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Although the genomes of many microbial pathogens have been studied to help identify effective
drugtargetsandnoveldrugs,sucheffortshavenotyetreachedfullfruition.Inthisstudy,wereporta
systems biological approach that efﬁciently utilizes genomic information for drug targeting and
discovery, and apply this approach to the opportunistic pathogen Vibrio vulniﬁcus CMCP6. First, we
partially re-sequenced and fully re-annotated the V. vulniﬁcus CMCP6 genome, and accordingly
reconstructed its genome-scale metabolic network, VvuMBEL943. The validated network model
was employed to systematically predict drug targets using the concept of metabolite essentiality,
along with additional ﬁltering criteria. Target genes encoding enzymes that interact with the ﬁve
essential metabolites ﬁnally selected were experimentally validated. These ﬁve essential
metabolites are critical to the survival of the cell, and hence were used to guide the cost-effective
selection of chemical analogs, which were then screened for antimicrobial activity in a whole-cell
assay. This approach is expected to help ﬁll the existing gap between genomics and drug discovery.
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Introduction
The genomes of a diverse spectrum of organisms have been
elucidated,notonlyforbetterunderstandingoftheirbiological
characteristics at the systems level, but also for various
biotechnological applications, such as identiﬁcation of new
drug targets. Discovering new antimicrobial targets and
consequently new antimicrobials is important, as drug
resistance of pathogenic microorganisms is an increasingly
seriousprobleminhumanhealthcaremanagement(Fischbach
and Walsh, 2009). There clearly exists a gap between genomic
studies and drug discovery as the accumulation of knowledge
on pathogens at the genome level has not successfully
transformed into the development of effective drugs (Mills,
2006; Payne et al, 2007). In previous efforts, genes predicted to
be conserved across microbial pathogens from comparative
genomic analyses were considered as drug targets, and
subjected to laborious gene disruption experiments for drug
target validation (Payne et al, 2007). The emergence of
genome-scale metabolic networks and simulation methods
has much accelerated this process, but they have mostly not
been linked to successful drug discovery (Thiele et al, 2005;
Jamshidi and Palsson, 2007; Oberhardt et al, 2008; Lee et al,
2009; Mazumdar et al, 2009; Kim et al, 2010a). Recent relevant
work attempted to overcome this problem by employing
virtual screening for chemicals against drug target enzymes
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(Shen et al, 2010). In this study, we dissected the genome of a
target microbial pathogen in detail, and subsequently devel-
oped a systems biological strategy that employs genome-scale
metabolicmodeling andsimulation foreffectivedrug targeting
and discovery. This strategy was used for identifying newdrug
targets in the opportunistic pathogen Vibrio vulniﬁcus CMCP6
as an example.
V. vulniﬁcus is a Gram-negative halophilic bacterium that is
found in estuarine waters, brackish ponds, or coastal areas.
V. vulniﬁcus belongs to g-proteobacterium in the family
Vibrionaceae, and it has been classiﬁed into three biotypes
on the basis of their biochemical and biological characteristics
(Gulig et al, 2005). Biotype 1, the dominant human pathogen,
and biotype 3, recently identiﬁed in people handling ﬁsh in
Israel, are considered to be the human pathogenic groups
(Jones and Oliver, 2009). Biotype 1 V. vulniﬁcus is an
opportunistic human pathogen that can attack immune-
compromised patients, and causes primary septicemia, necro-
tizedwound infections,andgastroenteritis.Consequently,this
bacterium is the major causative agent of death from ingestion
of raw or undercooked seafood, especially in people with liver
damage through, for instance, underlying hepatic disease and
heavy alcohol drinking habits. Primary septicemia progresses
rapidly through a fulminant course, which results in a high
mortality rate of over 50%, despite aggressive antimicrobial
and supportive shock therapies (Gulig et al, 2005).
Although V. vulniﬁcus isolates are generally reported to be
susceptible to commercial antimicrobial agents, including
doxycycline, third generation cephalosporins, and ﬂuoroqui-
nolones (Park et al, 1991; Hlady and Klontz, 1996; Bross et al,
2007), a substantial proportion of V. vulniﬁcus isolates from
the environment shows resistance to currently used antimi-
crobial agents (Radu et al, 1998; Baker-Austin et al, 2009).
Thus, new effective antibiotics to treat antibiotic-resistant
V. vulniﬁcus need to be developed. Consequently, we
previously searched V. vulniﬁcus genes preferentially ex-
pressed in patients for potential drug targets, and found that
many metabolic genes were speciﬁcally induced in vivo,
suggestingthatspeciﬁcmetabolicpathwaysareessentialforin
vivo survival and virulence of this pathogen (Kim et al, 2003;
Lee et al, 2007). These results motivated us to proceed to a
systems biological analysis of the genome and drug targeting
of this pathogen.
Figure 1 Reconstruction of genome-scale metabolic network and its use for drug targeting and discovery. (A) Genome-scale metabolic network of V. vulniﬁcus
CMCP6, VvuMBEL943, was reconstructed using genome annotation data, information from databases, literature, and experiments. As a result, the metabolic network
has a coherently organized set of biochemical reactions along with information of their genes and proteins. (B) Once validated, it was employed for drug-targeting
simulations using constraints-based ﬂux analysis for predicting essential metabolites. In this study, consuming reactions associated with essential metabolites were
experimentally validated by knocking out corresponding genes. (C) Finally, structural analogs of essential metabolites were collected from the chemical compound
library, and used for drug discovery through whole-cell screening.
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re-sequenced and fully re-annotated for genomic studies
and reconstruction of its genome-scale metabolic network
VvuMBEL943. Drug targets were systematically predicted
from the simulation and analysis of the metabolic network
VvuMBEL943, and were experimentally validated. Informa-
tion from predicted drug targets was then used to identify
novel antibiotic compounds from chemical library (Figure 1).
It is expected that this strategy would allow identiﬁcation of
novel antimicrobial targets, and consequently effective
antimicrobials for other pathogens of importance, in a cost-
effective manner.
Results
General features of V. vulniﬁcus CMCP6 genome
Aftertheinitial submission of theV. vulniﬁcus CMCP6genome
data to GenBank in 2002 (AE016795 and AE016796), we re-
sequenced the genomic regions assembled in low quality and
low depth, and subsequently re-annotated the whole genome.
The updated genome information was deposited to GenBank
under the accession numbers AE016795.3 (chromosome 1)
and AE016796.3 (chromosome 2). V. vulniﬁcus CMCP6 has
two circular chromosomes of 3281866bp (chromosome 1)
and 1844830bp (chromosome 2) with no plasmids. The sizes
of the chromosomes were reduced by 78bp (chromosome 1)
and 23bp (chromosome 2) after the sequence update. The
average GþC contents of chromosome 1 and 2 are 46.45 and
47.12%, respectively. Comparison of generic genomic features
ofthesixselectedVibrio speciesissummarizedinFigure2and
Supplementary Table I. Among the six Vibrio species, the
overall genome organization of V. vulniﬁcus CMCP6, such as
chromosomal size or gene content, appears to be most similar
to that of Vibrio parahaemolyticus, a gastroenteritis-causing
pathogen (Figure 2 and Supplementary Figure 1). Also, close
genomic comparison between the two V. vulniﬁcus chromo-
somes suggests that horizontal gene transfer is responsible for
the diversiﬁcation of each genome, leading to an increase in
ﬁtness of this organism under varying environmental condi-
tions (Quirke et al, 2006). Between the two chromosomes, the
location of metabolic genes was more biased to chromosome
1; 75.4% of metabolic genes are located on chromosome 1,
which takes up 65.3% of the total nucleotide sequence
(Supplementary Table I). However, genes associated with
propanoate,butanoate,and nitrogen metabolismarerelatively
more likely to be present on chromosome 2.
Comparative genomic analysis
Proteins encoded in the two chromosomes of V. vulniﬁcus
CMCP6 were compared with those of ﬁve other completely
sequenced Vibrio genomes in order to estimate their overall
similarity with respect to gene content. It was found that
75.6% of the V. vulniﬁcus CMCP6 proteins matched with 40.1
and 31.4% of the V. parahaemolyticus and V. harveyi proteins,
respectively, as identiﬁed by the reciprocal BLAST best hits
(E-value o10
 5). Phylogenetic distribution of the unidirec-
tional best hits using V. vulniﬁcus CMCP6 proteins as
queries revealed that 40.9% of the proteins from V. vulniﬁcus
CMCP6 chromosome 1 are most similar to those found on
V. parahaemolyticus chromosome 1, but the proportion
decreased to 31.1% for chromosome 2. This observation
suggests that the V. vulniﬁcus CMCP6 chromosome 2 is more
prone to diversiﬁcation for better adaptation to the environ-
ment than its chromosome 1. Other lines of evidence suggest
that the chromosome 2 of Vibrio species is more diverse in
size, gene content, and gene order (Heidelberg et al, 2000;
Makino et al, 2003). In addition, the genome sequences of
Vibrio species revealed that the smaller chromosome 2 does
not have an authentic chromosomal replication origin, but
rather has a plasmid-like replication origin (Egan and Waldor,
2003). It was thus hypothesized that chromosome 2 was
originally acquired as a megaplasmid, which subsequently
acquired some essential genes (Heidelberg et al, 2000),
supporting the diversiﬁcation of chromosome 2.
Next, to identify the conserved gene sets among the Vibrio
genomes, proteins from CMCP6 and ﬁve other Vibrio species
were clustered using BLASTCLUST. The thresholds were set at
60% identity and 70% length coverage, which are stricter than
the conventionally used thresholds (35% identity and 80%
length coverage) for identifying functions of proteins being
compared. As a result, 1587 clusters (1625.7±5.9 proteins)
ranging from 27.3 (V. harveyi) to 42.7% (V. ﬁscheri) of total
proteins were obtained. Although the distribution of con-
served genes was rather uniform among the compared
genomes, genes unique to each genome that were not
clustered varied signiﬁcantly (1348.3±224.3 proteins). This
impliesthat largerVibrio genomestend toexpandtheirgenetic
repertoire while maintaining the core genes at a constant level
without notable increase in paralogs. The percentage of
unclustered genes unique to each genome is also proportional
to the total number of genes (R
2¼0.9033). V. harveyi,
possessing the largest genome among the sequenced Vibrios
(6058377bp including a plasmid), is remarkable in that it has
as many as 38 unique clusters (43 members) totaling 653
genes, which can be operationally classiﬁed into paralogs.
Interestingly,mostofthemareofunknownfunction,andsome
encode reverse transcriptases with group II intron origin, and
probable transposases. In contrast, other Vibrio genomes
have only four unique clusters at most. With these ﬁndings,
genome evolution in Vibrios can largely be explained by
species-speciﬁc gene acquisition probably due to the horizon-
tal gene transfer, and/or paralog expansion. This pattern of
genomeevolutioninVibriosmayprovideﬁtnessadvantagesin
speciﬁc habitats, and potentially could contribute to drug
resistance.
We compiled a list of the 17 largest gene clusters, consisting
of 10 or more proteins commonly found in the 6 Vibrio
genomes (Supplementary Table II). These clusters, deemed
essential for metabolism and motility, occur in each genome in
rather uniform numbers, in contrast to genome-speciﬁc
clusters. Highly conserved genes found in bacterial genomes,
which do not have homologs in humans, are often considered
to be potential drug targets (Kim et al, 2010a). However, in the
present study, the metabolic genes of V. vulniﬁcus in these
clusters were not identiﬁed as essential ones, suggesting that
plurality of such genes in a given genus does not, at least in
Vibrionaceae, necessarily mean that those genes can serve as
drug targets. Metabolic pathways governed by these clustered
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isms throughout evolution.
Genome-scale metabolic network of V. vulniﬁcus,
VvuMBEL943
With the newly annotated genome of V. vulniﬁcus CMCP6,
a genome-scale metabolic network was reconstructed for
systematic studies on its metabolism and prediction of drug
targets (Figure 1). The in silico genome-scale metabolic
network, VvuMBEL943, is composed of 943 reactions and
765 metabolites, and covers 673 genes (Table I and Supple-
mentary TablesIII and IV). For this process,relevant metabolic
information from the Kyoto Encyclopedia of Genes and
Genomes (KEGG) (Kanehisa et al, 2006), TransportDB (Ren
and Paulsen, 2005), and MetaCyc (Caspi et al, 2008) was
manually curated along with the genome annotation data and
literature to upgrade the initial metabolic network towards a
more realistic one (Figure 1). The VvuMBEL943 possesses 792
reactions (84.0% out of whole reactions) assigned with
speciﬁc open reading frames (ORFs). Some reactions were
added even if they do not have assigned ORFs in order to
enable the in silico cell VvuMBEL943 to biosynthesize all the
constituents of biomass. The ability of V. vulniﬁcus to grow in
the deﬁned minimal (M9) medium (Table II) suggests that
these reactions need to be included for generating precursors
for biomass formation. Biomass composition was determined
based on the literature, genome annotation data, and experi-
ments performed in this study (Supplementary Table V) as it is
crucial for the metabolic network to correctly represent the
biosynthesis of major cell constituents, such as amino acids
and fatty acids, and ultimately the cell growth rate.
VvuMBEL943 was then validated by comparing the simu-
latedcellgrowthphenotypeobtainedbyconstraints-basedﬂux
analysis with the V. vulniﬁcus-speciﬁc experimental data
previously reported in the literature (Table II). Constraints-
based ﬂux analysis calculates intracellular ﬂuxes under
predeﬁned stoichiometric relationship of metabolites present
in the organism along with condition-speciﬁc constraints. The
objective function used was the maximization of cell growth
rate(Kimetal,2008)(seeMaterialsandmethods)becausethis
objective well describes the metabolic status of V. vulniﬁcus,
which proliferates inside iron-overloaded mice with an
Figure 2 Radar plots of genomic differences among six representative Vibrio species. Blue and red lines indicate chromosome 1 and 2 of each species, respectively,
for (A–E), while green line in (F) is for plasmid. Each plot reveals, for each organism, (A) chromosome size (bp), (B) percentage of GþC, (C) number of coding
sequences (CDS), (D) average size of CDS (bp), (E) percentage of base pairs involved in encoding proteins, and (F) plasmid sizes (bp) in VFI and VHA (others do not
have plasmids). Abbreviations are: VCH, V. cholerae N16961; VFI, V. ﬁscheri ES114; VHA, V. harveyi ATCC BAA-1116; VPA, V. parahaemolyticus RIMD 2210633;
VSP, V. splendidus LGP32s; VVU, V. vulniﬁcus CMCP6. Detailed numbers for each category are also shown in Supplementary Table I.
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et al, 2007). In this study, cell survival under the given genetic
and environmental (growth media) conditions is of particular
interest. Initially, 16 out of 18 cases were predicted to be
consistent with the experimental data, which suggested that
further improvement of the model was needed. For instance,
our earlier version of the metabolic network did not show
growth in M9 medium with maltose despite possessing a
maltose utilization system, which differed from experimental
data showing cell growth on maltose (Lim et al, 2005) (Case
15). It was discovered that VvuMBEL943 did not possess an
enzyme that metabolizes glucose, generated from maltose in
the cell (Boos and Shuman, 1998). Thus, a reaction catalyzed
by glucokinase (EC 2.7.1.2) was added to VvuMBEL943,
despite its absence in the genome annotation, in order to
properly reﬂect cell growth on maltose. Finally, for Case 2, the
growth of the gmhD mutant in AB medium (Kim et al, 2007a)
was inconsistent with the simulation result. GmhD (EC
5.1.3.20) is a critical enzyme involved in the biosynthesis of
lipopolysaccharide, which should operate in the growing cell.
Deletion of the gmhD gene greatly impaired the growth of
V. vulniﬁcus by resulting in the biosynthesis of a truncated
inner-core oligosaccharide (Kim et al, 2007a). As GmhD was
predicted to be essential using VvuMBEL943, the signiﬁcantly
retarded growth phenotype observed in the reported experi-
ments (Kim et al, 2007a) suggests that the simulation result is
not too inaccurate. As a result of the validation process, the
simulationaccuracyofVvuMBEL943 wasimproved tosupport
the results of 17 out of 18 experimental cases (Case 2 was
counted as an inconsistent result here). Thus, the validated
VvuMBEL943 represents the metabolic characteristics of
V. vulniﬁcus well, and can be employed for further simula-
tions. In addition to this, topological features of VvuMBEL943,
namely average path length and network diameter, were
characterized. They appeared to be more similar to those of
average bacteria than eukaryotes and archaea, and more
similar to those of V. cholerae than Escherichia coli (Ma and
Zeng, 2003), which manifests that VvuMBEL943 properly
conveys the distinct features of V. vulniﬁcus (Supplementary
Table VI).
Systems drug targeting
The main objective of constructing VvuMBEL943 in this study
is to predict potential drug targets by system-wide analysis of
the metabolic network (thus, systems drug targeting) for the
effective treatment of V. vulniﬁcus. As biological systems are
optimizedthroughevolutiongivingthemrobustness,targeting
for antibacterial drugs can, in essence, be achieved by
disrupting the robustness of the pathogen, and thereby
effectivelysuppressing its growth(Kitano, 2007). In this study,
robustness is a crucial concept in predicting drug targets,
which can be generally deﬁned as the cellular ability to
maintain its biological processes against internal and external
perturbations, including disruption of genes and inactivation
of enzymes by chemical agents (Kitano, 2007; Kim et al,
2007b). In terms of metabolic simulations implemented in this
study, zero cell growth rate after perturbation indicates the
complete disruption of robustness in V. vulniﬁcus.
To achieve this goal, a set of drug target candidates was
predicted by taking a metabolite-centric approach. Metabolite
essentiality analysis is a concept recently introduced for the
study of cellular robustness to complement the conventional
reaction (gene)-centric approach (Kim et al, 2007b, 2010b).
The conventional reaction (gene)-centric approach has limita-
tions in understanding cellular robustness because function-
ally important reactions are usually backed up by alternative
pathways; thus, many important reactions are not necessarily
lethal to the survival of the cell after knocking out signiﬁcant
portion of genes. In contrast, metabolite essentiality analysis
observes changes in ﬂux distribution by removing each
metabolite from the in silico metabolic network. As a result,
major and rerouting reactions relevant to the metabolite to be
removed are all deleted from the cellular network. If this
removal causes zero cellular growth rate, then the robustness
of the cell is deemed completely disrupted.
Besidesitsroleofelucidatingcellularrobustness,metabolite
essentiality analysis can greatly facilitate drug screening and
design process. Metabolite essentiality analysis predicts
essential metabolites whose absence causes cell death. By
identifying the essential metabolites,it is possible to focus ﬁrst
on their structural analogs, instead of large random chemical
libraries, which substantially reduce the number of chemical
compounds to screen. Rationale for this approach is well
supported by Dobson et al (2009), who reported that
metabolite-likeness is a good criterion in designing a drug.
Also, it would facilitate rational design of drugs on the basis of
the structures of essential metabolites.
Table I Features of Vibrio vulniﬁcus CMCP6 genome and genome-scale
metabolic network VvuMBEL943
Features Value
V. vulniﬁcus CMCP6 genome
Chromosome 1
Size (bp) 3281866
No. of coding sequences (CDS) 2896
G+C content (%) 46.45
Chromosome 2
Size (bp) 1844830
No. of coding sequences (CDS) 1537
G+C content (%) 47.12
VvuMBEL943
No. of metabolic pathways in metabolic network 64
Total No. of reactions included in the network 943
No. of biochemical reactions 807
No. of reactions in carbohydrate metabolism 176
No. of reactions in energy metabolism 21
No. of reactions in lipid metabolism 71
No. of reactions in nucleotide metabolism 128
No. of reactions in amino acid metabolism 208
No. of reactions in metabolism of otheramino acids 27
No. of reactions in glycan biosynthesis and
metabolism
31
No. of reactions in metabolism of cofactors and
vitamins
139
No. of reactions in biosynthesis of macromolecules 6
No. of transport reactions 136
No. of metabolites 765
No. of reactions assignedwith open reading frames (ORFs) 792
Total no. of ORFs assigned in metabolic network 673
No. of ORFs from chromosome 1 517
No. of ORFs from chromosome 2 156
Average path length (APL) 7.311
Network diameter (ND) 28
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for the in silico cell VvuMBEL943 growing in an arbitrary
complex medium, in which cells are allowed to simulta-
neously uptake all the nutrients when respective transporters
exist. This is to account for the effects of various carbon and
nitrogen sources available inside the host (e.g., human) for V.
vulniﬁcus, and to predict solid drug targets over a wide range
of conditions because the essentiality of metabolic reactions
can be conditionally different. As a result, 193 metabolites
were identiﬁed to be essential to the cell (Figure 3 and
Supplementary Table VII). It is obvious that larger number of
essential metabolites will be predicted if fewer input transport
reactions are made available during the simulation, and the
results will become more condition-dependent.
For the characterization of this initial set of 193 essential
metabolites, they were grouped into their relevant submeta-
bolism, and charted on the graph as functions of the portion of
essential metabolites, average number of reactions that
surround the essential metabolites, and average essentiality
of reactions constituting the submetabolisms (Figure 4 and
SupplementaryTableVIIandVIII;seeMaterialsandmethods).
In this analysis, cofactor and vitamin metabolism contained
thelargest numberof essentialmetabolites, followedbyamino
acid and lipid metabolisms, which are indicated with numbers
in the parentheses for each submetabolism (Figure 4). Mean-
while, lipid metabolism topped average essentiality of meta-
bolic reactions, while nucleotide metabolism had the most
abundant reactions surrounding essential metabolites. As
large sets of essential metabolites were found in the
metabolisms of cofactors, vitamins, lipids, and amino acids
even when these compounds (or precursors) were provided in
the arbitrary complex medium (simulating human body
condition), there is a high probability of identifying drug
targetsinthesemetabolisms.Furthermore,thisanalysisshows
that the portions of essential metabolites (third numbers for
each submetabolism in Figure 4) and the average essentiality
of reactions in each submetabolism were overall well
correlated. The submetabolism containing a larger portion of
essential metabolites, represented by a bigger bubble size in
Figure 4, tends to have a higher average essentiality of
reactions. Finally, nucleotide metabolism has the largest
average number of reactions surrounding essential metabo-
lites, probably because it includes the nucleotide salvage
pathway, which is highly interconnected, and possesses
several important energy carriers, such as ATP. Such high
value in this category leads to the possibility that one of those
surrounding reactions might also be present in the host
organism, including human. In fact, as discussed later, no ﬁnal
essential metabolites were selected from this nucleotide
metabolism partly because of this reason. Taken together,
analysis of essential metabolites provides several important
features of each submetabolism in this prokaryotic organism,
in particular with regard to the drug target selection. In
addition, synthetic lethality caused by essential metabolites
Table II Comparison of the growth phenotypes of V. vulniﬁcus CMCP6 and VvuMBEL943
Case
no.
Reaction ID Knocked-
out gene
ORF Metabolism Medium CMCP6 VvuMBEL
943
References
1 R300/R301 cya VV11123 Purine metabolism Heart infusion broth Y Y Kim et al (2005)
2 R648 gmhD VV10796 Lipopolysaccharide
biosynthesis
AB medium Y
a N Kim et al (2007a)
3 R484/R489 ilvC VV11077 Valine, leucine, and
isoleucine biosynthesis
Dulbecco’s modiﬁed
eagle medium (DMEM)
Y Y Kim et al (2003)
4 R484/R489 ilvC VV11077 Valine, leucine, and
isoleucine biosynthesis
Luria-Bertani (LB) Y Y Kim et al (2003)
5 R277/R278 purH VV11227 Purine metabolism DMEM N N Kim et al (2003)
6 R277/R278 purH VV11227 Purine metabolism LB Y Y Kim et al (2003)
7 R519/R520/R521/
R522/R524/R527/
R528/R529
putA VV21118 Arginine and proline
metabolism
M9, proline N N Kim et al (2002)
8 R519/R520/R521/
R522/R524/R527/
R528/R529
putA VV21118 Arginine and proline
metabolism
M9 without NH4Cl,
proline, yeast extract
Y Y Kim et al (2002)
9 R904/R906/R907 putP — Proline transporter
(permease)
M9, proline Y Y Kim et al (2002)
10 R904/R906/R907 putP — Proline transporter
(permease)
M9 without NH4Cl,
proline, yeast extract
Y Y Kim et al (2002)
11 R342 pyrH VV11861 Pyrimidine metabolism DMEM N N Kim et al (2003)
12 R342 pyrH VV11861 Pyrimidine metabolism LB N N Kim et al (2003)
13 R110/R111 wbpP VV10780 Aminosugars metabolism LB Y Y Park et al (2006)
14 — — — — M9, proline Y Y Kim et al (2002)
15 — — — — M9, maltose Y Y (N)
b Lim et al (2005)
16 — — — — M9, glucose Y Y This study
17 — — — — M9, glycerol Y Y This study
18 — — — — Alkaline peptone
water (APW)
Y Y Warner and
Oliver (2007)
N, no growth; Y, growth.
aGrowth of the gmhD mutant was signiﬁcantly impaired.
bParentheses in Case 15 indicate predicted growth of the earlier version of VvuMBEL943 before upgrades.
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reactions (Supplementary Table IX).
Essential metabolites of V. vulniﬁcus predicted with
VvuMBEL943 were compared with two Gram-negative
bacteria, E. coli and Helicobacter pylori whose genome-scale
metabolic networks were previously reported (Reed et al,
2003; Thiele et al, 2005). The percentage of essential
metabolites in V. vulniﬁcus was 25.2%, which is comparable
to that of E. coli (24.8%), but is much lower than that of
H. pylori (40.9%). The smaller genome size (1.7Mbp) of
H. pylori seems to be the reason for the higher percentage of
essential metabolites. In addition, 98 essential metabolites
predicted in V. vulniﬁcus were also predicted as essential in
both E. coli and H. pylori. These 98 commonly predicted
essential metabolites are those highly associated with biomass
composition (Supplementary Table X). The numbers of
essential metabolites exclusively identiﬁed in E. coli and
H. pylori were 21 and 17, respectively.
As not all enzymes associated with essential metabolites
satisfy the requirements to be good drug targets, this initial
set of essential metabolites were ﬁltered on the basis of
predetermined criteria, mainly organism speciﬁcity and
maximal impact on the biological robustness, in order to
reducethenumberofinitialtargetcandidateswhileidentifying
the most effective ones (Figure 3) (Kim et al, 2010a). The
ﬁrst step is to remove so-called currency metabolites, such
as ATP and NADH, which universally exist across organisms;
30 essential metabolites were removed from the candidate
list. Next, metabolites consumed by multiple reactions (X2)
were only considered, removing 81 metabolites. Selection
of essential metabolites consumed by multiple reactions is
based on the rationale that a drug mimicking the structure
oftheessentialmetabolitewillhaveahigherchanceofbinding
to multiple enzymes involved in multiple reactions. This
means that it might be possible to reduce the chance of
resistance development by single enzyme mutation in the
Figure 3 Prediction of essential metabolites and systems-oriented drug targeting. On the top left, ovals and boxes indicate reactions and metabolites, respectively.
Disrupted reactions are indicated with dotted lines along with crosses. Numbers next to each arrow indicate the number of essential metabolites survived after each
ﬁltering step, while list of metabolite abbreviations on the right side of each step shows the essential metabolites removed. Essential metabolites go through a series of
ﬁltering criteria. First, currency metabolites, which refer to metabolites that participate in many reactions, such as ATP and NADH, are removed. Then, essential
metabolitesconsumed by multiple reactions are further selectedin order tominimize the likelihood of resistance developmentwhile inhibiting the growth of the pathogen
at sufﬁciently low concentration by simultaneously disturbing multiple targets. Finally, essential metabolites that also exist in human or that are associated with enzymes
homologous to human proteins are removed in order to avoid any possible side effects in humans.
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Silver, 2007).
The last two steps are the comparison against human
metabolism to avoid possible side effects of drugs attacking
metabolites or homologous enzymes in the human body.
Essential metabolites were removed if they are present in the
comprehensivehumanmetabolicnetwork(Duarteetal,2007),
causing an additional 66 metabolites to be removed. Also,
BLASTP was performed on the enzymes consuming the re-
mainingessentialmetabolitesagainsthumanproteinstoremove
homologous ones (E-value smaller than 0.01). As a result, ﬁve
essential metabolites were predicted, including 2-amino-
4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine (AHHMP),
D-glutamate (DGLU), 2,3-dihydrodipicolinate (DHDP), 1-deoxy-
D-xylulose 5-phosphate (DX5P), and4-aminobenzoate (PABA)
(Table III and Figure 5). All these essential metabolites possess
twooutgoingreactions,whichhavemostlybeendemonstrated
to be good drug targets through experimental evidence.
Interestingly, DX5P is a critical intermediate for isoprenoid
biosynthesis and peptidoglycan assembly in bacteria, and
thus its surrounding enzymatic reactions have been suggested
to be promising drug targets, although underexplored yet
(Walsh, 2003).
Experimental validation of drug targets
The ﬁve ﬁnally selected essential metabolites, which were
predicted through the metabolite essentiality analysis and
subsequent ﬁltering process using the criteria of organism
speciﬁcity and maximal impact on the biological robustness,
have a total of nine consuming reactions catalyzed by seven
enzymes, each encoded by a single gene (Figure 5 and Table
III). These seven genes were selected as drug targets, and
subjected to furtherexperimental validation. It is interestingto
note that all of these genes are located on chromosome 1,
which is known to contain mostly housekeeping genes as
discussed above.
To validate the essentiality and lethality of the ﬁnal drug
targets, each gene was knocked out by the insertion of a
suicide vector in the chromosome or by in-frame deletion by
using the allelic exchange method (Materials and methods).
The essentiality of the gene was judged by whether or not a
speciﬁcmutantforeachgeneis created (Figure5). Ifanytarget
gene is essential for the survival of V. vulniﬁcus, introduction
of an insertion or deletion mutation to the gene should be
lethal. For the ﬁve target genes, VV10567, VV11175, VV11644,
VV11691, and VV11866, it was not possible to create insertion
or deletion mutants by any means after massive experimental
trials. For glutamate racemase (VV11175), it was originally
predicted to be nonessential in silico because VvuMBEL943
obtains DGLU from the arbitrary complex medium, which, at
ﬁrstglance,appearstocontradictourexperimentalresults.Yet,
gene knockout experiments were performed in a rich (heart
infusion) medium, which is composed of eukaryotic ingre-
dientslackingDGLU.Accordingtothis,essentialityofVV11175
was predicted again with the transporter for DGLU uptake
blocked in VvuMBEL943, and VV11175 was then predicted to
be essential, which becomes consistent with the experimental
Figure 4 Initial set of 193 essential metabolites grouped into their relevant submetabolisms charted on the graph as functions of the portion of essential metabolites
(colored bubbles), average number of surrounding reactions (y axis) and average essentiality of whole reactions constituting the submetabolism (x axis). Data for each
submetabolismarelabelednextto,orinsidethebubble;thethreenumbersinsequencerepresenttheaverageessentialityofmetabolicreactions,theaveragenumberof
surrounding reactions, and the bubble size (representing the portion of essential metabolites). Numbers in the parentheses indicate the number of essential metabolites
in each submetabolism. The submetabolism (bubble) with the average essentiality of reactions closer to the value of 1 means that it has a higher portion of essential
reactions. In this analysis, metabolism of cofactors and vitamins contained the largest number of essential metabolites, followed by amino acid and lipid metabolisms.
Meanwhile, lipid metabolism topped average essentiality of reactions, while nucleotide metabolism had most abundant reactions surrounding essential metabolites.
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tion of DGLU also predicted the same 193 essential metabo-
lites. For two other target genes, VV10580 and VV11568,
deletion mutants could not be obtained, but insertion mutants
could be generated; these insertion mutants showed serious
growth defect and formed tiny colonies on heart infusion agar
plates. Taken together, seven essential drug targets identiﬁed
by the metabolite-centric approach together with ﬁltering
criteria could be experimentally validated to be lethal in
V. vulniﬁcus upon their removal.
Next, gene (reaction) essentiality simulations were also
performed for the seven drug target genes identiﬁed by
metabolite essentiality and subsequent analyses. All genes
except for VV11644 were predicted to be essential by in silico
gene essentiality simulations. On the other hand, all seven
genes were found to be essential by experiments. There seems
to be a nutritional component in the arbitrary complex
medium that is absent in the heart infusion medium, which
made VV11644 nonessential in silico. Finally, although the
conﬁdence level of the results of the above gene knockout
experiments is high as massively repeated experiments have
been performed, they are so-called negative experiments (e.g.,
no mutant generation upon gene knockout). Thus, positive
killing experiments using drug-like molecules targeting the
candidates were also performed.
Screening of drugs based on essential metabolites
On the basis of the structural information on the ﬁve essential
metabolites predicted above, whole-cell screening was per-
formedusingtheiranalogsforpossibleantibacterialdiscovery.
In this study, screening only structural analogs of the essential
metabolites, rather than a whole chemical compound library,
reduces the typical number of chemical compounds to be
screened through high-throughput assays. Furthermore, re-
cent analyses indicating that effective drugs are structurally
highly similar to endogenous metabolites helped to motivate
this approach, in which compounds to screen were selected
based on their structural similarity to our predicted essential
metabolites (Dobson et al, 2009).
For the identiﬁcation of potential antibiotics that can
efﬁciently kill V. vulniﬁcus, we screened 352 chemical
compounds, which are structurally similar to one of the ﬁve
essential metabolites, obtained from Korea Chemical Bank at
Korea Research Institute of Chemical Technology (Daejeon,
Korea). Among several hit compounds, compound 24837, an
analog of PABA, was the most potent in terms of cell inhibition
capability (Figure 6A). An in vitro enzyme assay conﬁrmed
that compound 24837 targets dihydropteroate synthase
(Supplementary Figure 2).
In order to more precisely characterize compound 24837, a
time-kill assay was performed. As a result, the minimal
inhibitory concentration (MIC) and the minimal bactericidal
concentration (MBC) of compound 24837 were determined to
be2and4mg/ml,respectively(Figure6B).Noviablecellswere
observed in 3h after the treatment with 4mg/ml of compound
24837, while cells (1.8 10
7CFU/ml) were completely killed
within 1h when treated with 8mg/ml of compound 24837. The
steepness of killing curves obviously shows that compound
24837, selected from our systematic approach, has good
bactericidal activity against the pathogen V. vulniﬁcus. Mean-
while, sulfamethoxazole, an existing chemotherapeutic agent
for V.vulniﬁcus,whichalsointerfereswith folatebiosynthesis,
failed to inhibit the growth even at 8mg/ml (Figure 6B). In the
cases of the existing antimicrobials, the MBC ranges of
gentamicin and enoxacin for susceptible E. coli strains are
1.2–1.9 and0.6–0.8mg/ml, respectively(Liuet al,2004),while
the MBC range of vancomycin against methicillin-resistant
Staphylococcus aureus is 0.5–2.0mg/ml (Vidaillac et al, 2009).
Thus compound 24837, without further improvement, is
found to possess sufﬁcient antibacterial activity against
V. vulniﬁcus. Although the small-molecule drug identiﬁed
here needs to be further optimized by considering other
aspects of good antibiotics, the proof-of-concept approaches
taken in this study can serve as a general strategy for
discovering novel antibiotics and drugs based on systems-
level analysis of metabolic networks.
Table III Final drug targets selected from the metabolite-centric approach
Essential
metabolites
ORFs Metabolism E.C. No. Enzyme Previous studies
AHHMP VV11644 Folate biosynthesis 2.7.6.3 2-Amino-4-hydroxy-6-
hydroxymethyldihydropteridine
pyrophosphokinase
Blaszczyk et al (2007); Derrick (2008)
AHHMP, PABA
a VV11691 Folate biosynthesis 2.5.1.15 Dihydropteroate synthase Berglez et al (2005); Valderas et al (2008)
DGLU VV11175 D-Glutamine and
D-glutamate metabolism
5.1.1.3 Glutamate racemase Baba et al (2006); Lundqvist et al (2007)
DGLU VV10580 Peptidoglycan
biosynthesis
6.3.2.9 UDP-N-acetylmuramoylalanine–
D-glutamate ligase
El Zoeiby et al (2003); Baba et al (2006);
Strancar et al (2007)
DHDP
b VV10567 Lysine biosynthesis 1.3.1.26 Dihydrodipicolinate reductase Cirilli et al (2003); Hutton et al (2007)
DX5P VV11866 Biosynthesis of steroids 1.1.1.267 1-Deoxy-D-xylulose-5-phosphate
reductoisomerase
Rohdich et al (2001); Walsh (2003)
DX5P VV11568 Vitamin B6 metabolism 2.6.99.2 Pyridoxine 5-phosphate synthase Garrido-Franco et al (2002)
AHHMP, 2-amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine; DGLU, D-glutamate; DHDP, 2,3-dihydrodipicolinate; DX5P, 1-deoxy-D-xylulose 5-phosphate;
PABA, 4-aminobenzoate.
aPABA has two outgoing reactions encoded by the same ORF, VV11691, ‘PABA+AHHMD-PPI+DHPT’ (R738) and ‘PABA+AHHMP-DHPT’ (R739). The latter
reaction is shared by AHHMP and PABA. See Supplementary Table IV for metabolite abbreviations.
bDHDP also has two outgoing reactions encoded by the same ORF, VV10567. Two outgoing reactions are ‘DHDP+NADPH-NADP+TDHDP’ (R501) and
‘DHDP+NADH-NAD+TDHDP’ (R502). See Supplementary Table IV for metabolite abbreviation.
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In this study, we reported a systems biological approach for
characterizing an organism and transforming genomic infor-
mation into efﬁcient drug discovery. The V. vulniﬁcus genome
was partially re-sequenced and fully re-annotated as accurate
initial genomic information is crucial for a better under-
standing of this organism, as well as subsequent metabolic
modeling and prediction of drug targets. Then, the genome-
scale metabolic network VvuMBEL943 was reconstructed and
used to predict drug targets through a metabolite-centric
approach. Finally, structural information on ﬁve essential
metabolites was used to select structural analogs for whole-
cell antibiotic screening, resulting in several hit compounds,
one of them being compound 24837, which showed a MIC
of 2mg/ml.
The use of the systems biological approaches, especially
reconstruction and simulation of genome-scale metabolic
networks, appears to be very effective during the early phase
of drug discovery because it systematically predicts condition-
independent drug targets at agreeable accuracy and in a
cost-effective manner, as demonstrated in this study. Also,
metabolite essentiality analysis was proven to be useful for
the initial selection of structural chemical analogs and
subsequent whole-cell screening. Furthermore, it should be
possible to rationally design a drug based on the structure of
essential metabolites, which could simultaneously disrupt
their associated outgoing reactions (Dobson et al, 2009;
Kim et al, 2010b).
It should be noted that genes excluded from our ﬁnal drug
target list do not necessarily mean that they are completely
disqualiﬁed as drug targets. In fact, the criteria for selecting
ﬁnal drug targets in this study might have been ratherstrict, so
that well-known target genes were unexpectedly ﬁltered out.
For instance, the pyrH gene encoding UMP kinase, which was
previously validated asan essential in vivo survival factor (Lee
et al, 2007), was not considered for the ﬁnal target gene
because the reaction catalyzed by this gene product interacts
withcurrencymetabolites,includingATP,ADP,UMP,andUDP
despite their essentiality in the organism. The corresponding
reaction (R342, PyrH) was predicted to be essential in silico
(Supplementary Table VIII) and humans do not have this
enzyme, suggesting it to be an ideal target as well. Hence,
enzymes associated with discarded essential metabolites are
Figure 5 Metabolic map showing genes knocked out for the validation of ﬁnal drug targets, including VV10567, VV10580, VV11175, VV11568, VV11644, VV11691,
and VV11866. All disrupted genes, displayed as colored lines on the metabolic map, were essential. Red and green lines indicate no mutant constructed and insertion
mutant created with low frequency, respectively. Five essential metabolites are represented with their structures. Multiple arrows indicate reactions not shown in the
metabolic pathway. Metabolite abbreviations can be found in Supplementary Table IV.
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need to be undertaken, for instance rational design of the drug
that binds to the target enzyme instead of analog-based
screening so as not to disturb essential metabolites present in
humans. Moreover, new criteria that also consider genes
preferentially expressed in vivo upon infection (Kim et al,
2003) need to be taken into account.
Although metabolic genes of V. vulniﬁcus are distributed
both in chromosome 1 and 2, it is intriguing to ﬁnd that 23.8%
of metabolic genes in chromosome 1 (123 out of 517 genes)
were predicted to be essential during the cell growth in an
arbitrary complex medium, while only 11.5% of those in
chromosome 2 (18 out of 156 genes) were essential (Supple-
mentary Table VIII). Also, the ﬁnal drug target genes listed in
Table III are exclusively encoded by chromosome 1. This
supports the hypothesis that smaller chromosomes, namely
chromosome 2, of Vibrio species might have evolved from a
plasmid origin because they possess fewer essential metabolic
genes compared with chromosome 1, and lack authentic
chromosomal replication origins (Heidelberg et al, 2000). The
primordial plasmid seems to have evolved to the second
chromosome by expanding its genomic repertoire through
gene acquisition by horizontal gene transfer. For the same
reason, chromosome 1 seems to be the primordial genome
because it contains a higher portion of essential metabolic
genes or housekeeping genes necessary for the cellular
survival. This type of analysis will be useful for the studies
on essential metabolic genes in microorganisms having
multiple chromosomes.
Two existing antibacterials, sulfamethoxazole and trimetho-
prim, which are known to be bacteriostatic, deserve further
discussioninassociationwithcompound 24837. Sulfamethox-
azole structurally competes with PABA, while trimethoprim
speciﬁcally inhibits dihydrofolate reductase. Their synergistic
combination occasionally shows bactericidal activity by
inhibiting sequential enzymes of folate biosynthetic pathway
(Allan and Moellering, 1985; Zander et al, 2010). However,
compound24837, astructuralanalogofPABA,screenedinthis
studyshowedbactericidalactivityagainstV.vulniﬁcusCMCP6
without combination with other inhibitors. This unexpected
ﬁnding goes against the long-lasting idea that PABA analog
interfering with folate biosynthetic pathway is bacteriostatic,
and suggests that ﬁnal targets predicted from our systems-
oriented drug-targeting studies could serve as bactericidal
targets.
Finally, further studies need to be done on the proof-of-
concept hit compound 24837 and thestrategypresentedin this
study. Although an in vitro enzyme assay showed that
compound 24837 inhibits dihydropteroate synthase, it might
also bind to other enzyme targets, in which case several
system-wide approaches, for instance omics techniques
(Freiberg et al, 2004), can be undertaken. Also, it is necessary
to examine whether the strategy employed in this study can
efﬁciently identify bactericidal compounds for other targets as
well,andwhether theidentiﬁedhit compoundsarefeasiblefor
futureoptimization.Afterall,alltheseeffortswouldcontribute
to ﬁlling the gap between genomic studies and drug discovery.
Materials and methods
Bacterial strains and growth conditions
V. vulniﬁcus CMCP6 is a clinical isolate from Chonnam National
University Hospital, and was used throughout this study. Bacterial
cells were grown in 2.5% NaCl M9 mediumwith glucose orglycerolas
a sole carbon source for experimental validation of the constructed
VvuMBEL943. They were also grown in heart infusion or Mueller
Hinton medium for speciﬁc studies as detailed below.
Genome sequence update, re-annotation, and
analysis
After our initial submission of V. vulniﬁcus CMCP6 genome data to
GenBank in 2002 (AE016795 and AE016796), mainly based on COG
annotation, the genome sequence and annotation were substantially
improved. First, re-sequencing of low-quality and/or low-depth
regions was performed by Sanger sequencing of PCR products directly
ampliﬁedfromthegenomicDNA.Editingofannotationaccompanying
the sequence correction, as well as modiﬁcation of translation
initiation sites inferred from the BLASTanalysis results against known
protein sequence database were conducted manually. Hypothetical
genes overlapping with other known genes or ones with extrinsic
evidence were chosen and reassigned with putative gene names. The
Figure6 Ahitcompound24837screenedfromthewhole-cellscreeninganditstime-killassay.(A)Structuresofessentialmetabolite4-aminobenzoate(PABA)andits
structural analog 24837 are shown along with minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) values of the analog 24837 against
V. vulniﬁcus CMCP6. (B) Time-kill assays of compound 24837 and sulfamethoxazole, an existing chemotherapeutic agent that also interferes with folate biosynthetic
pathway. It should be noted that the curve for 1mg/ml of 24837 (yellow triangle) is covered with that for 0.5mg/ml (closed rectangle) as they showed similar values.
Data points and error bars indicate mean values±s.d.
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et al, 2003) and COG (Tatusov et al, 2003). The entire genome
sequence was also subjected to automatic annotation by the RAST
server (Aziz et al, 2008). When assigning functional information to
each gene, the highest priorities were given to the TIGRFAMs search
results. Finally, the remaining genes were given names after the
automatic RAST annotation. As the RAST server with its own gene
prediction method was used, information was assigned only when the
gene calls fully overlap with original ones. The species of the family
Vibrionaceae chosen for the comparative analysis were V. parahae-
molyticus RIMD 2210633 (Makino et al, 2003), V. cholerae N16961
(Heidelberg et al, 2000), V. ﬁscheri ES114 (Ruby et al, 2005), V. harveyi
ATCCBAA-1116,andV.splendidusLGP32(LeRouxetal,2009).Protein
sequences were clustered using the BLASTCLUST program of NCBI.
Reconstruction of V. vulniﬁcus genome-scale
metabolic network
The genome-scale metabolic network was reconstructed according to
the procedure previously described (Kim et al, 2007c; Thiele and
Palsson, 2010). Reactions and metabolites incorporated in VvuM-
BEL943 are shown in Supplementary Tables III and IV. Brieﬂy, the
initial version of the network was ﬁrst reconstructed based on the
metabolic pathways of V. vulniﬁcus present in the KEGG (Kanehisa
et al, 2006). Even though the metabolic information of V. vulniﬁcus
present in the KEGG might show some discrepancies with our genome
annotation data, those maps were ﬁrst adopted to generate compre-
hensive overall picture of the metabolic network. Then, the metabolic
network was reﬁned based on the information present in MetaCyc
database (Caspi et al, 2008) and the genome annotation data to
conﬁrm reaction reversibility, gene-to-protein relationships, and
predicted functions for each gene incorporated in the network. In the
same way, transport reactions were incorporated based on the best
available information from literature and TransportDB (Ren and
Paulsen, 2005). Also, biomass composition was determined based on
literature information except for the compositions of amino acids and
fatty acids, which were experimentally determined in this study
(Supplementary Table V). Finally, the network was validated by
comparing simulation results with experimental results from litera-
ture, and accordingly further reﬁned so as to use it for in silico drug-
targeting analysis. The metabolic network was reconstructed using
MetaFluxNet (Lee et al, 2003), and was converted into GAMS (GAMS
Development Corp., Washington DC, USA) for subsequent drug-
targeting simulations. The SBML version of VvuMBEL943 was
deposited to the BioModels Database (accession number: MOD-
EL1011300000).
Constraints-based ﬂux analysis for model
validation and simulation
Constraints-based ﬂux analysis is an optimization-based simulation
technique based on the mass balance of intracellular metabolites (Kim
etal,2008;Parketal,2009).Asetofmassbalancesaroundmetabolites
yields a stoichiometric model Sij vj¼0 with an assumption of
pseudosteady state, in which Sij is a stoichiometric coefﬁcient of a
metabolite i in the jth reaction, and vj is ﬂuxof the jth reaction given in
mmol/gDCW/h.Themetabolicnetworkconstructedinthisstudyisan
underdeterminedsystem,havinginﬁnitesetsofsolutions.Thus,linear
programming (LP) was performed by maximizing the cell growth rate,
represented by the overall macromolecule composition of the cell
(Supplementary Table V), with constraints of mass conservation,
reaction thermodynamics and metabolic capacity for each reaction in
order to calculate intracellular ﬂuxes as follows:
X
j2J
Sijvj ¼ bi; 8i 2 I ð1Þ
ajpvjpbj; 8j 2 J ð2Þ
where bi is the net transport ﬂux of metabolite i, and is zero if the
metaboliteisanintermediate.ajandbjarethelowerandupperbounds
of the ﬂux of the jth reaction, respectively. Hence, aj is set to zero for
irreversible reactions, while unconstrained for reversible reactions.
Uptake rates of nutrients were assumed to be o2mmol/gDCW/h,
based on the growth characteristics of V. ﬁscheri (Droniuk et al, 1987).
For simulation of VvuMBEL943 under the undeﬁned complex media,
including heart infusion and Luria-Bertani (LB) broth, uptake rates for
the nutrients, mostly amino acids and nucleotides, examined to be
present in those complex media were constrained to be o2mmol/
gDCW/hiftheirassociated transporters arepart ofthe network model.
Except for the validation simulations, all the simulations were
performed under the arbitrary complex medium.
For metabolite essentiality, each metabolite was removed one by
one. This was simulated by deleting all the outgoing (consuming) or
incoming (producing) reactions around the metabolite to be removed.
Details can be found from our previous paper (Kim et al, 2007b). If
removal of a certain metabolite leads to zero cell growth, this
metabolite is deemed essential (Supplementary Table VII).
Analysis of essential metabolites
For the analysis of essential metabolites presented in Figure 4, 193
essential metabolites were grouped into their relevant submetabolism,
which refers to the metabolism that contains a biosynthetic pathway
for a corresponding metabolite. For instance, NAD was included in
metabolism of cofactors and vitamins as this submetabolism contains
biosynthetic pathways for NAD. In this analysis, all nucleotides,
includingATP,weregroupedintonucleotidemetabolism,andoxidized
and reduced thioredoxin (OTHIO and RTHIO), CO2,N H 3, and Pi were
not considered, as they do not belong to a particular metabolism. The
portionof essential metabolitesin each submetabolismwascalculated
bydividing the number of essential metabolites by the total number of
metabolitesparticipatinginthesubmetabolism.Averageessentialityis
the average value of essentiality (¼1 gD/g) of reactions in the
submetabolism where gD and g each indicates the predicted cell
growth rate of the single reaction mutant and the wild-type using
constraints-based ﬂux analysis under the arbitrary complex medium
(Edwards and Palsson, 2000; Guimera et al, 2007). To calculate the
growth rate of the single reaction mutant, each reaction was deleted
one at a time by setting the reaction ﬂux to zero while maximizing the
biomass formation equation (Supplementary Table VIII).
Construction of predicted drug target gene
mutants of V. vulniﬁcus by homologous
recombination
Toverifyessentialityofpredicteddrugtargetgenes,speciﬁcmutantsof
the genome project strain V. vulniﬁcus CMCP6 were constructed both
by the insertional inactivation with a suicide vector and the in-frame
deletion by using allelic exchange (Miller and Mekalanos, 1988). For
the insertional inactivation of the drug target genes, truncated drug
target gene fragments were ampliﬁed by PCR and ligated into the
suicidevector pDM4 (Milton et al, 1996).The primerpairs used for the
ampliﬁcationofthetruncatedDNAfragmentsofeachgenearelistedin
Supplementary Table XI. The PCR primers had overhangs recognized
by one of restriction enzymes cutting the multicloning site of pDM4.
The ligated DNA was transformed into E. coli SY327 l pir. Plasmids
ampliﬁed in E. coli SY327 l pir were isolated and transformed into
E. coli SM10 l pir (Miller and Mekalanos, 1988), and subsequently
transferred to V. vulniﬁcus CMCP6 by conjugation. Chloramphenicol-
resistanttransconjugantshavingthemobilizedplasmidintegratedinto
their chromosome by homologous recombination were selected on
thiosulfate-citrate-bile-sucrose (TCBS) agar plates containing 2mgo f
chloramphenicol/ml as described previously (Milton et al, 1996).
Nonpolar in-frame deletion mutants of the putative drug target genes
were constructed by a modiﬁed overlap extension PCR method
(Horton et al, 1989). The method consists of two steps. First, we
ampliﬁed two PCR fragments corresponding to upstream and down-
stream regions of each target gene by normal PCR reaction. Reverse
primer for upstream fragment and forward primer for downstream
fragment included DNA sequences (bolded) at the 50 end that are
complementary toeachother thatwould allowjoining ofthe upstream
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two fragments were puriﬁed by a PCR puriﬁcation kit (QIAGEN), and
then used as templates for next overlap extension PCR reaction. The
second PCR was performed using the forward primer of upstream
fragment and the reverse primer of downstream fragment having
appropriate restriction overhang for cloning, which will generate a
fused DNA fragment consisting of up and downstream DNA fragments
generated in the ﬁrst PCR step. The resulting in-frame deleted
amplicons of each of the genes were cloned into pCR
s2.1-TOPO
s
vector (Invitrogen). The DNA insert having in-frame deletion of each
gene was re-cloned to pDM4, and the resulting ligate was transformed
intoE.coliSM10lpir.TheplasmidinE.coliSM10lpirwastransferred
to V. vulniﬁcus CMCP6 by conjugation, and the transconjugants were
selected on TCBS agar plate containing chloramphenicol as described
above.Thetransconjugantswereplatedonto2.5%NaClheartinfusion
agarplatecontaining10%sucrosetoselectclonesthatexperiencedthe
second homologous recombination event, forcing excision of the
vector sequence and leaving only a mutated or wild-type allele of the
genes. Each insertional or in-frame deletion mutation was conﬁrmed
by PCR of the chromosomal DNA from respective mutants.
Whole-cell screening of structural analogs of
essential metabolites
Structural analogs of the ﬁve essential metabolites were searched
against the in-house chemical compound library of Korea Chemical
Bank at Korea Research Institute of Chemical Technology (Daejeon,
Korea)usingthePipelinePilot6.0withMDLPublicKeysandTanimoto
coefﬁcient of 0.5 as a cutoff (Accelrys, San Diego, CA, USA). As a
result, 352 chemical analogs were identiﬁed, and subsequently
obtained from Korea Chemical Bank. Whole-cell screening for the
MIC was then performed in accordance with the CLSI guideline (CLSI,
2006). Bacterial culture grown to OD600 of 0.10–0.15 in Mueller Hinton
broth were 10-fold diluted, and 5ml was inoculated into each well
whoseworkingvolumewas100mlinthe100-wellplates.Bacterialcells
were then cultured for 20h and monitored using BioScreen C (Oy
Growth Curves Ab Ltd, Finland). Chemical compound or analog was
consideredactiveifthemaximalconcentrationofcellstreatedwiththe
corresponding chemical compound showed more than 80% reduction
compared with that of the untreated control sample.
Time-kill assay
V.vulniﬁcusCMCP6 was culturedin 2.5% NaCl heart infusionbroth at
371C overnight with shaking at 220r.p.m. Next day, the culture was
diluted by 100-fold with 2.5% NaCl Mueller Hinton broth containing
compound 24837 or sulfamethoxazole. Viable cell counting was
carried out by the pour plating method at 0, 1, 3, and 6h after
incubation at 371C without agitation.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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